Sana Biotechnology

Sana focuses on advancing potentially curative medicines for patients, emphasizing urgency and care in therapeutic development.

Sana advances drug candidates to disrupt treatment possibilities for diverse diseases.

Sana’s platform repairs genes in cells or replaces cells in the body to treat diseases.

Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition of Oscine Corp.

The page shares updates on Sana Biotechnology’s progress in developing engineered cells as medicines.

Sana Biotechnology secured over $700 million in initial financing, with investors including ARCH Venture Partners and the Canada Pension Plan Investment Board.

Ke Liu, M.D., Ph.D., joined Sana as Head of Regulatory Affairs & Strategy after 17 years at the U.S. Food and Drug Administration.

Sana Biotechnology launched to develop engineered cells as medicines, leveraging advances in cell reprogramming and replacement.

Sana offers employees comprehensive benefits, including coverage from their first day and programs tailored to a diverse workforce.

Alise S. Reicin, M.D., serves as CEO and President of Tectonic Therapeutic, Inc., and previously led clinical development at Celgene Corporation.

Hans Bishop is the Executive Chairman of Sana Biotechnology and the Chief Executive officer of GRAIL.

Michelle Seitz, CFA, founded MeydenVest Partners in 2022 and previously led Russell Investments as CEO from 2017.

Sana's team includes executives, board members, investors, and scientists with deep experience in cell and gene therapy.

Sana is bringing together great people and the best technologies to deliver on the challenging promise of engineering cells to be medicines.

Sana develops engineered cells as medicines to treat diseases.

Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease.